Drug Profile
LGM 2605
Alternative Names: LGM-2605Latest Information Update: 31 Mar 2023
Price :
$50
*
At a glance
- Originator The Scripps Research Institute; University of Pennsylvania
- Developer LignaMed; National Institute of Allergy and Infectious Diseases
- Class Antiasthmatics; Antifibrotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Asthma; Lung disorders; Pulmonary fibrosis; Radiation injuries
- No development reported Chemotherapy-induced damage
Most Recent Events
- 31 Mar 2023 Preclinical development is ongoing in Radiation-injuries and lung disorder
- 30 Mar 2023 LGM 2605 is still in preclinical trials for Pulmonary fibrosis in USA (LignaMed pipeline, March 2023)
- 30 Mar 2023 Preclinical trials in Asthma in USA (PO) (LignaMed pipeline, March 2023)